New drug combo tested for advanced breast cancer in chinese women

NCT ID NCT02499146

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested the drug palbociclib (combined with letrozole) in 26 postmenopausal Chinese women with a specific type of advanced breast cancer (ER+, HER2-). The main goal was to see how the drug moves through the body and to check for safety. The study is complete, and results help guide future use in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib (a targeted cancer drug) and Letrozole (a hormone therapy)
What this could lead to: If successful, this study could help confirm that palbociclib works similarly in Chinese patients, supporting its use as a treatment for advanced breast cancer in this population.
What could go wrong: This is a very early (Phase 1) study with only 26 participants, focused on drug levels in the body, not on curing cancer. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Beijing Cancer Hospital/Oncology department

Beijing, Beijing Municipality, 100142, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, 100021, China
Guangdong General Hospital/Department of Breast Surgery

Guangzhou, Guangdong, 510080, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China
The first hospital of jilin university

Changchun, Jilin, 130021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.